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ABSTRACT  
This manuscript describes the study protocol, recruitment outcomes, and baseline participant 
characteristics for the Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) 
trial. SPACE is a pragmatic randomized comparative effectiveness trial conducted in multiple 
VA primary care clinics within one VA health care system. The objective was to compare 
benefits and harms of opioid therapy versus non-opioid medication therapy over 12 months 
among patients with moderate-to-severe chronic back pain or hip/knee osteoarthritis pain despite 
analgesic therapy; patients already receiving regular opioid therapy were excluded. Key design 
features include comparing two clinically-relevant medication interventions, pragmatic eligibility 
criteria, and flexible treat-to-target interventions. Screening, recruitment and study enrollment 
were conducted over 31 months. A total of 4491 patients were contacted for eligibility screening; 
53.1% were ineligible, 41.0% refused, and 5.9% enrolled. The most common reasons for 
ineligibility were not meeting pain location and severity criteria. The most common study-
specific reasons for refusal were preference for no opioid use and preference for no pain 
medications. Of 265 enrolled patients, 25 withdrew before randomization. Of 240 randomized 
patients, 87.9% were male, 84.1% were white, and age range was 21-80 years. Past-year mental 
health diagnoses were 28.3% depression, 17% anxiety, 9.4% PTSD, 7.9% alcohol use disorder, 
and 2.6% drug use disorder. In conclusion, although recruitment for this trial was challenging, 
characteristics of enrolled participants suggest we were successful in recruiting patients similar 
to those prescribed opioid therapy in usual care.  
 
Keywords: opioid analgesics; analgesics; chronic pain; back pain; osteoarthritis  
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1. Introduction  
 
Chronic musculoskeletal pain conditions are among the most prevalent and disabling of chronic 
diseases.1 As a result of a decades-long expansion in opioid analgesic prescribing, treatment of 
chronic pain with long-term opioid therapy has become common practice. 2,3 Evidence has not 
kept up with practice. Although short-term trials suggest that opioids can produce small short-
term reductions in pain intensity,4,5 evidence for long-term effectiveness is largely absent. A 
systematic review conducted in 2014 and updated in 2016 found no controlled opioid trials that 
examined effects on pain, function or quality of life at one year or longer.6 Evidence regarding 
harms of long-term opioid therapy is mostly derived from retrospective observational studies and 
few studies have published data on patient-reported adverse symptoms. 
 
A 2014 National Institutes of Health Pathways to Prevention panel on the role of opioids in the 
treatment of chronic pain identified “a clear need for well-designed longitudinal studies of 
effectiveness and safety of long-term opioid use in the management of chronic pain.”7 The panel 
report noted barriers to conducting standard randomized controlled trials, such as difficulty 
recruiting and retaining participants, and suggested alternate and pragmatic study designs to 
address evidence gaps and inform clinical decision-making.  
 
This manuscript describes the study protocol and recruitment outcomes for the Strategies for 
Prescribing Analgesics Comparative Effectiveness (SPACE) trial, a pragmatic randomized 
comparative effectiveness trial conducted in a VA health care system. The objective of the trial 
was to compare benefits and harms of opioid versus non-opioid medication therapy over 12 
months. The study was designed to be maximally relevant to pain management in primary care 
practice and inform an important decision point in the care of patients with moderate-to-severe 
chronic pain—whether or not to initiate long-term opioid therapy. We chose non-opioid 
medication therapy as the comparison intervention for opioid therapy because we believed it to 
be the most clinically-relevant alternative pain management strategy. 
 
2. Methods  
 
2.1 Design overview 
 
SPACE is a pragmatic randomized comparative effectiveness trial with masked outcome 
assessment comparing opioid therapy versus non-opioid medication therapy over 12 months for 
patients with chronic back pain or hip or knee osteoarthritis pain. Both interventions (opioid 
therapy and non-opioid therapy) were delivered using a telecare collaborative management 
model and a treat-to-target approach aiming for 30% improvement in pain and progress toward 
individualized goals.  
 
Patients treated for back, hip, or knee pain at primary care clinics in the Minneapolis Veterans 
Affairs (VA) Health Care System were identified through automated searches of the electronic 
medical record (EMR) and screened by telephone for eligibility. Patients with chronic back pain 
or hip or knee osteoarthritis pain of at least moderate severity despite analgesic use were eligible. 
Eligible patients who provided informed consent and completed a baseline assessment visit were 
randomized to either the opioid therapy arm or the non-opioid therapy arm. Randomization was 
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at the individual level, restricted by primary pain location (back or hip/knee), and implemented 
using a computer program to conceal allocation. 
 
Each arm included multiple medications that were available by prescription within the VA health 
care system during the study period. In both arms, pain medication management was provided 
for 12 months, with medication therapy tailored to individual patient preferences and adjusted 
within the assigned treatment arm to achieve therapeutic targets. Outcomes were evaluated by 
masked assessors at 3, 6, 9, and 12 months after enrollment. To offset costs of participation, 
participants were paid $100 in cash after completion of baseline, 6, and 12 month assessments 
and $20 by check after completion of the 3 and 9 month assessments. No incentives were 
provided for attendance at clinical intervention visits. The study was approved by the 
Minneapolis VA Institutional Review Board. 
 
2.2 Pragmatic trial design 
 
The intent for the SPACE trial was to be as pragmatic as possible, evaluating benefits and harms 
of opioid therapy in close to usual care conditions, and to maximize applicability to primary care 
practice settings. We considered pragmatic design principles outlined in the pragmatic-
explanatory continuum indicator summary (PRECIS) in SPACE trial development.8 Table 1 and 
Figure 1 show pragmatism of trial domains according to the updated PRECIS-2 tool.9  
 
Table 1: PRECIS-2 scores for trial domains 
 Domain Score Rationale 
1 Eligibility criteria 5 We aimed to enroll a broad sample of primary care patients 
who would potentially receive either opioid or non-opioid 
medications in practice, including those with mental health and 
medical diagnoses that typically lead to exclusion from 
analgesic clinical trials.10 Exclusion criteria were the minimum 
necessary to ensure patient safety and internal validity. 
2 Recruitment path 1 Intensive recruitment efforts were necessary because of 
unappealing aspects of the trial, especially randomization to 
opioid or non-opioid therapy for 12 months. 
3 Setting 5 We identified patients who attended a visit at multiple primary 
care clinics within a local health care system. 
4 Intervention 
organization* 
3 The most pragmatic approach would have been primary care 
prescribing of intervention drugs, but we didn’t think this was 
feasible because of established analgesic prescribing habits 
and opinions.11,12 To ensure participants received the treatment 
to which they were assigned, a study clinical pharmacist 
managed study medications, using an approach similar to 
pharmacist management of other chronic diseases in VA 
primary care.13 
5 Flexibility: intervention 
delivery* 
5 Both opioid and non-opioid therapy interventions were 
delivered with a high degree of flexibility in choice and dosing 
of medications. 
6 Flexibility: intervention 5 We did not actively restrict non-study prescribing. Participants 
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adherence* were not withdrawn for receiving non-study medications. 
Participants were allowed nonpharmacological pain 
treatments. Patients who did not tolerate study medications 
were encouraged to continue in the study. We used standard 
clinical adherence monitoring practices.  
7 Follow-up 2 Outcome assessment included extensive patient-reported data 
collection every 3 months to obtain long-term data and 
minimize missing data for patient-reported measures. We 
offered alternate response modes or short forms if needed. 
8 Outcome 5 The primary outcome is long-term and highly relevant to 
patients with chronic pain. 
9 Analysis 5 We used intent-to-treat analysis of data for all randomized 
participants with any follow-up outcomes. 
*Both arms had the same approach to organization, flexibility, and adherence. Scores for each 
domain are rated from 1 (least pragmatic) to 5 (most pragmatic). 
 
2.3 Eligibility 
 
The target population was primary care patients with moderate-to-severe chronic back pain or 
hip or knee osteoarthritis pain despite analgesic therapy. Inclusion criteria were further defined 
as follows: 
 Moderate-severe pain intensity and interference with function: The PEG scale, a 3-item 
multidimensional pain measure, was used to define pain severity.14 Eligibility criteria were a) 
a score of ≥5 on the average pain intensity item and b) a mean score of ≥5 on the two 
functional items (interference with enjoyment of life; interference with general activity). 
 Chronic back pain or hip or knee osteoarthritis pain as the primary pain condition: These 
conditions were selected because they are among the most common indications for long-term 
opioid therapy.15-18 Chronic pain was defined as pain present nearly every day or every day 
for ≥6 months. The primary pain diagnosis was identified by patient self-report during the 
screening interview and confirmed by a targeted review of each patient’s medical records. At 
least minimal documented evidence of the diagnosis (such as inclusion in a primary care 
problem list or visit note) was required. Patients with both chronic back pain and hip/knee 
osteoarthritis pain were stratified based on the most bothersome condition at the time of 
eligibility screening.  
 Despite analgesic therapy: To ensure participants were appropriate for opioid therapy, 
eligibility criteria required ongoing pain despite use of at least one analgesic medication.  
 
Patients were excluded if they were currently receiving long-term opioid therapy, had conditions 
that could interfere with outcome assessment, or had contraindications to all drugs in either arm. 
Specific exclusion criteria were as follows:  
 Current long-term opioid therapy: EMR data were used to identify patients with any long-
acting opioid (i.e., methadone, transdermal fentanyl, or any sustained-release opioid) 
dispensed in the prior three months or any prescription for ≥ 60 tablets/capsules of short-
acting DEA schedule II or III opioid dispensed in the prior three months.  
 Conditions that could interfere with outcome assessment: Patients were excluded if they met 
any of the following criteria: a) schizophrenia, bipolar disorder, or other psychotic disorder; 
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b) moderately severe cognitive impairment, defined as ≥2 errors on a brief cognitive 
screener;19 c) anticipated back, knee, or hip surgery within 12 months; d) anticipated life 
expectancy of less than 12 months; or e) unable to complete outcome assessments for 12 
months for any reason.  
 Contraindications to all drugs in either arm: In general, contraindications for individual 
medications include known allergy, previous serious adverse effect, or failure of a previous 
adequate trial. Because of the diversity of drug classes in the non-opioid therapy arm, 
contraindications to all drugs in that arm were much less common than contraindications to 
all drugs in the opioid therapy arm. Class-level contraindications to opioid therapy were 
consistent with VA/DoD clinical practice guidelines20 and included the following: 
o Psychiatric instability: This was defined as current uncontrolled severe depression, 
severe PTSD, or suicidal ideation and patients were excluded only if they had severe 
symptoms that were not actively treated. Patients with severe untreated symptoms on 
the initial screening interview were provided with information about accessing mental 
health care and offered the opportunity of rescreening later. 
o Active substance use disorder (SUD) or history of opioid use disorder: We did not 
exclude patients with SUD (other than opioid use disorder) in remission or those with 
recent illicit drug use but no apparent SUD. In addition to information obtained 
during the eligibility screening process, urine drug test (UDT) results obtained at the 
baseline assessment were considered in evaluation of this criterion. Patients who 
reported drug use or had a UDT positive for an illicit drug were asked if they were 
willing to discontinue drug use during the study. If they agreed, follow-up questions 
from the NIDA-modified ASSIST questionnaire21 were asked and, for those with a 
positive UDT, follow-up testing was done prior to randomization. Participants who 
had a lower risk substance involvement score (0-3) on the ASSIST questionnaire and 
a negative follow-up UDT were randomized to a treatment group and continued in the 
study; those with a substance involvement score ≥ 4 and a negative follow-up UDT 
were considered by the PI on an individual basis.  
o Documented or suspected prior misuse or diversion of prescribed controlled 
substances 
o Current regular benzodiazepine use: Patients were excluded if they reported using 
any benzodiazepine more than once or twice in a typical week. 
o Fibromyalgia and migraine headache: Because opioid therapy may worsen these 
conditions, patients were excluded if they reported fibromyalgia or headaches 
interfering with activities ≥3 times a week. 
 
2.4 Recruitment, eligibility screening, and enrollment  
 
Primary care providers (PCPs) were informed of the study and asked to provide written 
authorization for the study to approach patients on their panels for participation. Over the 
recruitment period, 77 PCPs were contacted for permission; of these, 62 agreed, 8 refused, and 7 
didn’t respond. The PI’s primary care panel was not contacted. Potentially eligible patients were 
identified from primary care panels through administrative database searches, which identified 
patients who had been given a relevant diagnosis at a primary care visit in the prior month and 
who were not currently dispensed long-term opioids.  
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Each month during the enrollment period, database searches were updated and a sample of 
patients from among those identified was selected for telephone screening. To maximize 
recruitment of potentially eligible women, we selected all women and a random sample of men 
for screening. After four months of recruitment, because many patients were being screened out 
and not eligible due to mild pain, we also added a database search selection preference for 
patients with a pain score ≥5 at the most recent visit. Specifically, men with pain score ≥5 were 
preferentially selected for screening, along with all women. If fewer than the target number of 
patients was identified for the month, additional men with pain scores of 0-4 were selected at 
random from among the remainder to reach the target number. At four months, we also 
determined that PTSD screening questions could be removed from the telephone eligibility 
screening interview due to low yield and we determined that recruitment efforts were 
exceptionally low-yield for patients > 80 years of age or living > 50 miles from the Minneapolis 
VA Medical Center, so we stopped selecting these patients for eligibility screening. Patients 
could also be referred directly from primary care to study eligibility screening. 
 
Potentially eligible patients selected for screening were mailed an invitation letter describing the 
study and providing instructions for opting out of additional recruitment contacts. If they did not 
opt out, study personnel attempted to contact them by telephone to determine interest in 
participating and to conduct an eligibility interview. We made at least six attempts on two 
different days at three different times of the day before determining that a patient was 
unreachable. The screening interview assessed eligibility criteria in the following order: 1) pain 
condition and severity; 2) medication use; 3) depression and PTSD symptoms; 4) alcohol and 
drug use; 5) surgical plans and availability for 12 months; 6) cognitive screening test. 
Subsequently, the principal investigator completed a brief medical record review checklist to 
verify eligibility criteria. A face-to-face enrollment visit was scheduled for patients who were 
eligible and interested in participating.  
 
At the enrollment study visit, study personnel completed the informed consent process with 
patients. After participants provided written informed consent, they were asked to complete 
baseline interviews, questionnaires, and testing, including urine and blood samples. If 
participants reported having an additional primary care or pain care provider outside the VA 
healthcare system, they were asked to provide authorization to contact non-VA health care 
providers for the duration of the study. We sent non-VA care providers a letter describing the 
study, a link to study registration at clinicaltrials.gov, and a request for past-year medical 
records. The first intervention visit with the pharmacist care manager was scheduled at the end of 
the enrollment visit. 
 
2.5 Randomization, allocation concealment, and masking 
 
Randomization was conducted at the first visit with the intervention pharmacist care manager; 
for most participants, this occurred approximately one week after the enrollment/baseline 
assessment visit. This delay allowed intervention clinicians to review urine drug testing (UDT) 
results prior to randomization. The pharmacist care manager completed a check of patients’ 
understanding of the study and provided an opportunity to ask additional questions or express 
concerns prior to randomization. 
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A repeated measure completely randomized design with replication was used for the randomized 
treatment assignment and further control of subject variability. Randomization was restricted by 
primary pain location (back or hip/knee) as blocks. To ensure balanced numbers of participants 
with back pain or hip/knee pain, within-block randomizations were conducted in sequential 6-
patient runs. To maintain allocation concealment, the pharmacist care manager randomized the 
patient using a study computer application program prepared by the study data team.  
 
Masking participants to treatment assignment was not feasible due to the complexity of the 
medication therapy interventions. The study pharmacist care manager and supervising physician 
investigators were also aware of treatment assignment. Study medications were included in 
participants’ EMR medication list, marked by an “INV” prefix (for “investigational”), and thus 
visible to all treating clinicians. Outcome assessors were masked to treatment arm assignment 
and did not enter the EMR. Study intervention clinicians were masked to outcome assessment 
data. Data team members were the only personnel with complete access to the study computer 
application and databases; other study personnel had restricted access appropriate to their role in 
the study.  
 
2.6 Interventions 
 
Participants were randomized to receive one of two active interventions, either opioid therapy or 
non-opioid medication therapy, for 12 months. 
 
2.6.1 Overview of study interventions 
 
In both intervention arms, participants received active medication management delivered using a 
telecare collaborative management model that has been previously evaluated in VA primary 
care.22,23 The two arms differed only in the medications included. Each arm included multiple 
medications that were available by prescription within the VA health care system during the 
study period (see Table 2).  
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Table 2: Prescribing strategies and medications for intervention arms 
Step Opioid therapy arm Non-opioid medication arm 
First  Morphine IR*  Acetaminophen* 
 Oxycodone IR  Naproxen 
 Hydrocodone/acetaminophen Ibuprofen 
  Meloxicam 
  Celecoxib 
  Salsalate 
  Etodolac 
  Sulindac 
  Diclofenac 
  Diclofenac topical gel 
   
Second  Morphine SR Nortriptyline 
 Oxycodone SA Amitriptyline 
  Gabapentin 
  Lidocaine topical  
  Capsaicin topical  
   
Third Fentanyl transdermal Pregabalin 
  Duloxetine 
  Tramadol 
*Preferred initial medication selection. 
 
 
Pain medication therapy was tailored to individual patient preferences and adjusted within the 
assigned arm to achieve therapeutic targets. Participants entered the prescribing strategies at 
different levels, depending on their baseline medications and past medication histories. Their 
baseline medications may have been discontinued, adjusted to achieve an adequate therapeutic 
trial, or continued with the addition of adjunctive drugs, depending on their individual history of 
medication use (including dosing, scheduling, and adherence), therapeutic response, and adverse 
effects.  In general, each step of the prescribing strategies was tried before moving to the next 
step. The study protocol outlined principles and preferred practices for medication prescribing 
decision points, which are outlined for each arm below.   
 
Strategies employed to address medication tolerability problems depended on the adverse effect 
and patient preferences and included: 1) switching to a different medication; 2) lowering the 
medication dosage; 3) decreasing the frequency of dosing; 4) using medications on an as-needed 
only basis; or 5) prescribing medications for adverse symptom management. 
 
When participants did not demonstrate a response to maximized therapy within their assigned 
arm, regimens were adjusted to reduce the risk for medication-related harms by switching from 
scheduled to as-needed dosing or reducing dosage (if applicable). Participants who desired 
discontinuation of all medications in their assigned arm were assisted with tapering to 
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discontinuation (if applicable) and transition back to their pre-enrollment medication regimen. 
Study clinicians did not manage or adjust off-protocol pain medications. 
 
2.6.2 Opioid therapy  
 
Participants assigned to the opioid therapy prescribing strategy were initially started on 
immediate-release (IR) opioids, either morphine IR, hydrocodone/acetaminophen, or oxycodone 
IR. Opioid dosage was titrated to achieve pain treatment goals, with adjustments approximately 
every 4 weeks, to a maximum daily dosage of 100 morphine-equivalent (ME) mg. For 
participants without a clear response at a daily dosage of 60 ME mg, rotation to a different opioid 
was considered.  The opioid rotation process was guided by recommendations and equianalgesic 
dosing tables in the 2010 VA-DoD opioid guidelines.20 When a simpler dosing regimen or more 
consistent analgesia was preferred, long-acting opioids were considered. Single opioid therapy 
was preferred, but dual therapy with both a scheduled sustained-action (SA) opioid and an as-
needed IR opioid was considered according to participant needs and preferences. All participants 
assigned to the opioid therapy arm were prescribed a prophylactic bowel regimen to prevent 
constipation, most often docusate/sennosides or polyethylene glycol powder. Dose adjustments 
to these medications were made based on individual response.  
 
2.6.3 Non-opioid medication therapy 
 
Participants assigned to the non-opioid prescribing strategy were initially treated with a first-line 
analgesic drug—acetaminophen or a non-steroidal anti-inflammatory drug (NSAID) 
medication—unless first-line choices were clinically inappropriate, based on past medication 
trials and contraindications. Adjuvant oral therapies were usually added to an initial regimen, but 
were considered as initial options when first-line medications were deemed inappropriate. 
Topical products were considered when oral regimens were insufficient, poorly tolerated, or 
clinically less appropriate. Tramadol, an atypical opioid with mu opioid agonist effects and 
serotonin-norepinephrine effects that was not a controlled substance in the US when this study 
was launched, was included in the third-line and considered only when participants did not 
respond to other medications or combinations of medications. Failure to respond to an adequate 
trial of one drug in a given class did not eliminate other members of that drug class from 
consideration. Diclofenac 1% gel was added in the last year of the trial after it was added to the 
VA formulary; it was considered a first-line or adjuvant option when oral NSAIDs could not be 
used.  A low-dose proton pump inhibitor was prescribed to participants who were started on an 
oral NSAID and met gastrointestinal prophylaxis criteria from the Arthritis Foundation quality 
indicator set for safe use of NSAIDs.24 
 
2.6.4 Intervention delivery 
 
Both interventions were delivered using a telecare collaborative management approach tested in 
the Stepped Care to Optimize Pain Care Effectiveness (SCOPE) study and described in detail 
previously.22  This approach has two main components: optimized analgesic management by a 
care manager/physician team and symptom monitoring. For this trial, a single clinical pharmacist 
was the care manager and central intervention provider for both arms. Decisions about 
medication therapy were made during regular case management meetings of the pharmacist care 
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manager and study physician. Non-controlled medications were prescribed by the pharmacist 
care manager and controlled substances were prescribed by a study physician. Primary care 
clinicians were informed about patient progress and medication changes using care management 
notes entered in the EMR, which is consistent with usual consultant practice in the health care 
system.   
 
Participants were scheduled for their first intervention visit with the pharmacist care manager 
approximately one week after study enrollment. During this visit, a detailed history was obtained 
of prescription medication, over-the-counter medication, and herbal, vitamin, and supplement 
use. Participants’ preferences and concerns regarding pain medications were discussed and 
participants were asked to identify a goal pain score as well as at least one activity goal. Follow-
up intervention visits were scheduled approximately every four weeks until a stable medication 
regimen was established and then every four-to-twelve weeks, based on participant preference. 
The protocol specified that visits should be conducted in-person at least every six months when 
possible; other follow-up visits were scheduled in-person or by telephone, depending on 
participant preference.  
 
An interactive voice response (IVR) telephone system was used for symptom monitoring. IVR 
telephone calls were used for interval reassessment of pain and adverse effects and were usually 
scheduled seven days prior to intervention follow-up visits. The IVR script included the 3-item 
PEG pain scale, a patient global impression of pain change rating, the PHQ-4 item depression 
and anxiety screener, and questions about side effects, preference for medication change, and 
desire for a return call.14,25 Due to technical limitations of the IVR system used in this study, 
response options for the PEG scale had to be modified. Instead of the validated 0-10 rating scale, 
a modified 1-7 rating scale was used. Automated symptom monitoring by IVR was used solely 
as a clinical tool to assist with monitoring and adjusting therapy. It was not used to assess 
research outcomes.  
 
Decisions to change pain medications were made in a structured shared process. At each visit, 
symptom monitoring was reviewed and participants were asked about pain, sleep, side effects, 
and progress toward self-identified activity goals. Participants were encouraged to state their 
preferences regarding pain medications; these preferences, along with progress toward 
individualized goals, were the primary drivers of changes in therapy. When possible, participants 
were provided with options for medication adjustments and allowed to select their preferred 
option. Medication adjustments were made until pain management goals were achieved or all 
treatment options within the assigned arm were exhausted.  
 
2.6.5 Clinical adherence monitoring 
 
Multiple adherence monitoring strategies are recommended by clinical practice guidelines to 
reduce opioid-related harms.20,26 These strategies include written medication agreements 
outlining responsibilities of patients and prescribers; checking state prescription drug monitoring 
programs (PDMP); using urine drug testing; and assessing behaviors potentially associated with 
non-adherence. In this trial, we applied recommended monitoring strategies as follows: 1) a 
written medication agreement based on the VA model opioid therapy agreement was reviewed 
and signed at the first intervention visit; 2) the state PDMP website was checked at each visit and 
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anytime there was a clinical reason for concern; 3) urine drug testing was done at baseline and 
anytime there was a clinical reason for concern; and 4) a checklist of potential non-adherence 
behaviors was completed by the pharmacist care manager at each visit.27 We used the same 
approach to adherence monitoring in both arms to avoid introducing attention bias.  
 
To assist with general medication adherence, all participants were provided with a seven-day 
pillbox. An updated medication list and letter was provided to participants after every medication 
change and an individualized dosing calendar was used for more complicated medication 
titrations and tapers.  
 
2.7 Measures  
 
Study measures included patient-reported outcomes at baseline and at 3, 6, 9, and 12 months and 
test-based outcomes (physical, cognitive, and laboratory testing) at baseline and at 6 and 12 
months.  A full battery of patient-reported outcomes were collected by in-person interview and 
written questionnaire at baseline and 6 and 12 months; a subset was collected by telephone 
interview at 3 and 9 months. To minimize missing primary outcome data, patients who were 
unable to attend in-person follow-up assessment visits were asked to complete at least a core set 
of measures by telephone or, if they were unable to complete telephone interviews, by mailed 
questionnaire. Table 3 displays measures and timing of administration.  
 
Outcomes were collected by assessors who were masked to treatment arm assignment, including 
the study coordinator, one primary research assistant (RA), and one back-up RA. To establish 
rapport with participants, the coordinator and primary RA both participated in the baseline visit. 
The coordinator held training sessions with the RAs prior to and during data collection to ensure 
outcomes were assessed in a consistent manner.  
 
Table 3: Measures and assessment schedule  
Measure Data source 
Schedule (month) 
0
 
3 6 9
 
12 
Patient-reported measures       
   Brief Pain Inventory (BPI) interference and severity scales
28,29 Interview X X X X X 
   Abbreviated Roland-Morris disability scale
30 Interview X  X  X 
   Global rating of change*
31
 Interview  X X X X 
   Veterans RAND 12 Item Health Survey (VR-12)
32,33
 Interview X X X X X 
   Modified adverse symptom checklist
34
 Interview X X X X X 
   Multidimensional Fatigue Inventory
35,36
 Interview X  X  X 
   PROMIS Sleep Disturbance short form
37
 Interview X  X  X 
   Migraine Disability Assessment
38
 Interview X  X  X 
   Patient Health Questionnaire (PHQ)-8
39
 Interview X X X  X 
   Generalized Anxiety Disorder (GAD)-7
40
 Interview X X X  X 
   Primary Care-PTSD screener
41
 Interview X     X 
   Arizona Sexual Experience scale†42 Questionnaire X  X  X 
   Alcohol Use Disorders Identification Test (AUDIT) †43 Questionnaire X   X   X 
   Drug and tobacco use † Questionnaire X   X  X 
   Pain Medication Attitude Questionnaire†44 Questionnaire X    X 
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Measure Data source 
Schedule (month) 
0
 
3 6 9
 
12 
   Modified Prescribed Opioids Difficulties Scale (PODS)†‡45 Questionnaire X    X 
   Treatment expectations and preferences‖ Interview X     
   Pain co-intervention checklist† Questionnaire X X X X X 
   Hospitalizations and emergency department visits   Interview/EMR  X X X X 
   Falls Interview  X X  X 
   IU-TBANS cognitive test battery
46
 Interview X  X  X 
Physical tests       
   Fullerton Advanced Balance scale
47
 Exam X  X  X 
   Gait speed (6 meter)
48,49
 Exam X  X  X 
   Chair stand test
50
 Exam X  X  X 
   Grip strength
51
 Exam X  X  X 
   Cold pressor testing
52
 Exam X    X 
   Urine toxicology Laboratory X  X  X 
   Testosterone and estradiol  Laboratory X    X 
* “How would you describe your pain now, compared to when you started in our study?” Response 
options: much better, moderately better, a little better, no change, a little worse, moderately worse, much 
worse. 
† Completed independently on paper questionnaire form. 
‡ The PODS measure was adapted by changing “opiate” to “pain” medications in all questions. 
‖ Developed specifically for this study as described in text. 
 
 
2.7.1 Pain outcome measures 
 
As recommended in expert consensus guidelines for pain clinical trials, we assessed multiple 
pain outcome domains.53 The primary study outcome measure is the Brief Pain Inventory (BPI) 
interference scale, a seven-item measure of pain-related function. The main measure of pain 
intensity is the BPI severity scale. These BPI scales have been validated for use in numerous 
populations, including primary care patients with chronic pain.28,29,53 The abbreviated 11-item 
Roland-Morris disability scale was used as a secondary measure of pain-related function.30 A 
seven-grade patient-reported global rating of change question was used to assess patients’ views 
of overall improvement or worsening in pain.31  
 
2.7.2 Harm outcome measures  
 
The primary measure of adverse effects is a modified adverse symptom checklist that assesses 
number and severity of common symptoms and participants’ beliefs about whether or not 
symptoms are medication-related. The original checklist was developed to assess symptoms 
related to a variety of different medications among primary care patients.34 For this study, we 
modified the checklist by adding five symptoms reflecting common patient-reported side effects 
of analgesic medications (i.e., memory problems, dry mouth, trouble concentrating, sweating, 
and weight gain)54 not included in the original version. Secondary adverse outcomes included 
hospitalizations, emergency department visits, and falls. Hospitalizations and emergency 
department visits are identified by both medical record searches and patient report at outcome 
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assessment visits and counted from date of enrollment to 13 months after randomization. The 
World Health Organization system for standardized case causality assessment is used to 
determine whether the relationship between an event and analgesic use is probable or greater.55 
Falls were assessed by patient report at outcome assessment visits.  
 
2.7.3 Additional secondary measures 
 
Multiple secondary measures were assessed, as shown in Table 3. Drug and tobacco use were 
assessed with a single item screening test for drug use56 and questions from the National Survey 
on Drug Use and Heath and NIDA-modified ASSIST.21 
 
Participants were asked to complete ratings of treatment expectations and preferences. Items 
were based on previously published measures and modified for this study.57,58 These included 
ratings of effectiveness and safety of the two study arms (“In general, how [effective/safe] do 
you consider [opioid medications/non-opioid medications] for long-term treatment of pain?” 
with response options 0 “not at all effective/safe” to 10 “most effective/safe possible”); 
expectations for personal benefit from study participation (“In terms of pain, how much 
improvement do you think is likely for you personally during this study?” with options 0 “no 
improvement” to 10 “a great deal of improvement”); preference for study arm assignment (“For 
this study, you will be assigned to a treatment group by chance. Now, imagine if you were given 
a choice between groups. Considering what you know so far, which treatment group would you 
choose?”); and strength of preference (You said you would prefer the ______ arm. How strong is 
your preference?” with options 0 “no preference” to 10 “strongest possible preference”). 
 
At in-person assessment visits, participants were asked to complete the Fullerton Advanced 
Balance scale, a 10-item test that evaluates multiple dimensions of balance in independent 
adults.47,59 A chair stand test was conducted as the number of stands completed from a seated 
position in 30 seconds.50 Gait speed was assessed with a timed six-meter walk protocol.48,49 Grip 
strength was assessed with a Jamar hydraulic hand dynanometer.51 Cold pressor testing was done 
by immersing the hand in a circulating cold water bath at 1° C for up to 5 minutes. 52To assess 
cognition, the Indiana University Telephone-Based Assessment of Neuropsychological Status 
(IU-TBANS) was completed at in-person visits; this includes a battery of standard clinical 
instruments covering the following domains: attention, learning and recall, information 
processing speed, and verbal fluency.46  
 
Because no single measure is diagnostic of opioid misuse, data from multiple sources were used 
to assess the occurrence of behaviors suggestive of opioid misuse or substance use disorder.60 In 
addition to the measures in Table 3, clinical adherence data were collected at each intervention 
visit. 
 
2.7.4 Process measures 
 
The number and duration of pharmacist care manager visits and interactive voice response calls 
were extracted from electronic databases. 
 
2.7.5 Qualitative interviews 
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Qualitative semi-structured follow-up interviews were conducted with a subset of 40 trial 
participants, including 10 responders and 10 non-responders from each arm. The purpose of 
these interviews was to gain a better understanding of participants’ experiences in the trial and 
perceptions of the study interventions.  
 
2.8 Statistical considerations 
 
2.8.1 Sample size justification 
 
The sample size (total n= 276) was based on estimated treatment effects on the primary outcome 
measure, the BPI Interference score. A between-group treatment difference of 1 point in the BPI 
Interference score represents a minimum meaningful intervention effect.61 For our calculations, 
we assumed the standard deviation (SD) of the BPI Interference score in both arms would be 2.7, 
based on the intervention arm of a prior pain trial.62 A sample size of 115 in each arm was 
estimated to provide 80% power to detect a 1-point difference in the mean BPI Interference score 
between groups, assuming 2-sided alpha of 0.05. To allow for up to 20% attrition, we aimed 
enroll 276 patients.  
 
We estimated the planned sample size would provide 86% power to detect a 1-point difference in 
the BPI Severity score and 94% power to detect a 3-point difference in the Roland disability 
score. As a secondary measure of effectiveness, pain response was defined as a 30% 
improvement from baseline in the BPI Severity score and functional response as a 30% 
improvement in the BPI Interference score.61 Power to detect a 20% difference in response rate 
(0.25 vs. 0.45) was estimated to be 0.86.  
 
2.8.1 Statistical analysis 
 
We will use an intent-to-treat analysis approach, including all participants in the arm to which 
they were originally assigned. We will check randomization- induced balance by comparing the 
observed baseline characteristics and potential confounders between the two arms. Medication 
use at the end of the trial in each arm will be presented in a descriptive table, including numbers 
using each drug and mean daily dose. For opioids, doses will be described as morphine-
equivalent mg per day. For primary and secondary outcome measures, informative (non-
parametric) summary statistics with corresponding standard deviations will be presented. 
Distributional assumptions for outcome measures and error terms will be examined using 
goodness-of-fit tests and diagnostic graphs.   
 
We will initially compare group differences in scores on primary and secondary measures at each 
post-intervention time point, using a series of analyses of covariance (ANCOVA), which control 
for the baseline score as a covariate. For analyses of primary and secondary continuous measures 
(e.g., BPI scores, VR-12 scores), we will use mixed models of correlated within-block (i.e., back, 
hip/knee) repeated response measures. The models will have treatment group, categorical time 
points, and baseline values as fixed effects, with block and intercept as random effects. This 
Generalized Linear Mixed Modelling (GLMM) will be the conventional Gaussian mixed model 
for normally-distributed outcomes (e.g., BPI interference), a logistic mixed model with logit link 
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for the repeated-measures binary response outcomes (e.g., ≥ 30% improvement in BPI 
interference from baseline), and a Poisson (or Negative Binomial) mixed model with log link for 
the count outcomes (e.g., number of hospitalizations). GLMM with the same set of fixed and 
random effects for other possibly skewed outcome measure distributions (e.g., gamma, beta, log-
normal) will be used if the conventional transformation to normality is not satisfactory.  
 
3. Results  
 
3.1 Recruitment outcomes 
 
Screening, recruitment and study enrollment were conducted over a 31-month period (June 
2013-December 2016), with an average of eight new participants enrolled per month (range 2-
14). Figure 2 shows results of the recruitment process. In summary, of the 4491 patients who 
were contacted by telephone, 2383 (53.1%) were ineligible, 1843 (41.0%) refused, and 265 
(5.9%) enrolled. The most common reasons for ineligibility were not meeting pain location and 
severity criteria. Of the 1843 patients who refused, 696 (38%) cited no specific reason and 381 
(21%) cited time constraints or distance. The most common study-specific reasons for refusal 
were preference for no opioid use (n=272, 15%) and preference for no pain medications (n= 229, 
12%). Thirteen patients were counted as refusals because they did not show up for their 
enrollment appointment, after initially agreeing to participate.  
 
Table 4 shows demographic and clinical characteristics of patients who were identified as 
potentially eligible by the pre-screening searches of the EMR, according to the screening process 
outcome. Those who were not selected for telephone screening are notably more often male, 
older, and more likely to be a veteran of World War II or the Korean War than the other groups; 
these differences are consistent with the preferential selection of women and the decision at four 
months to stop selecting patients > age 80 years or with home addresses > 50 miles from the 
medical center. 
 
Table 4: Characteristics of patients selected for SPACE trial eligibility screening by 
screening outcome (n= 9,403) 
 
 
 
Not selected 
for telephone 
screening 
(n=3,836) 
Unable to 
contact by 
telephone 
(n=1,076) 
Screened 
and not  
eligible 
(n=2,383) 
Screened 
and 
refused 
(n=1,843) 
Enrolled 
(n=265) 
Age in years, mean (SD)  67.4 ± 17.9 51.7 ± 15.9 58.1 ± 14.4 58.4 ± 
15.0 
57.5 ± 
14.0 
Sex, % male 96.7 85.9 89.0 90.5 87.9 
Race, % white 85.6 77.8 81.0 82.0 84.1 
Period of military service, %      
     World War II, Korea  37.9 3.5 7.8 8.8 5.6 
     Vietnam War 35.8 36.8 50.7 50.2 50.6 
     Persian Gulf/Post-Vietnam 15.8 36.3 28.9 25.5 29.1 
     Iraq/Afghanistan 10.5 3.5 7.8 8.8 5.6 
Qualifying pain diagnosis, %      
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  Back pain 52.0 57.3 54.9 58.9 63.4 
  Hip or knee osteoarthritis 55.3 51.2 51.9 50.0 44.9 
Charlson comorbidity score, mean 
(SD) * 
1.07 ± 1.6  0.48 ± 1.0 0.87 ± 1.4  0.90 ± 1.5 0.90 ± 1.3 
Mental health diagnoses, * %      
  Depression 17.2 24.0 28.9 23.2 28.3 
  Anxiety 10.0 18.1 18.2 14.5 17.0 
  PTSD 6.6 8.2 10.8 8.8 9.4 
  Alcohol use disorder 8.0 11.5 15.4 9.7 7.9 
  Drug use disorder 2.8 4.1 8.3 2.6 2.6 
All values are from clinical and administrative databases. 
* Based on ICD-9 and ICD-10 diagnoses in the prior 12 months.  
 
 
3.2 Characteristics of participants 
 
Of 265 veterans who enrolled in the study, 25 withdrew prior to randomization. Ten were 
withdrawn by the research team for likely substance use disorder after positive drug testing 
results (n=8) or inadequate understanding of the study (n=2). The remaining 15 chose to 
withdraw due to no longer interested (n=8), concerns about opioid use (n=5), transportation 
issues (n=1), and health problems (n=1).   
 
Baseline characteristics of the 240 patients who were randomized are presented in Table 5.  The 
majority of randomized participants were white and male; the age range was 21-80 years (mean 
age 58.3 years). When asked, prior to randomization, which medication group they would prefer, 
a majority (51.3%) of participants expressed no preference, 28.8% preferred the opioid group 
and 20.0% preferred the non-opioid group. Perceived medication effectiveness was rated 7.8 for 
opioids and 5.7 for non-opioids on a scale of 0 “not effective at all” to 10 “most effective 
possible.” Perceived medication safety was rated 5.8 for opioids and 6.6 for non-opioids on a 
scale of 0 “not safe at all” to 10 “most safe possible”.  Participants reported high expectations for 
likely personal improvement during the study (mean 7.5 on a scale of 0 “no improvement” to 10 
“a great deal of improvement”). 
 
Table 5: Baseline characteristics of 240 participants randomized in the SPACE trial 
Age in years, mean ± SD 58.3 ± 13.7 (21-80) 
Sex male, n (%)  208 (86.7)  
Race/ethnicity, n (%)  
  White 207 (87.0)  
  Black/African-American 18 (7.6)  
  Native American/Alaskan Native 4 (1.7) 
  Native Hawaiian/Pacific Islander 2 (0.8)  
  Hispanic/Latino  2 (0.8) 
  Asian 1 (0.4) 
  Multiple race/ethnicity categories 4 (1.7)  
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Education ≥ 4-year degree, n(%) 60 (25.0) 
Employment, n(%)    
  Employed for wages 81 (34.2) 
  Self-employed 14 (5.9) 
  Retired 99 (41.8) 
  Other 43 (18.1) 
Primary qualifying pain diagnosis,* n (%)  
  Back pain 156 (65.0) 
  Hip or knee pain 84 (35.0) 
Substance use  
  Current smoker, n (%) 38 (22.6) 
  AUDIT score ≥ 8, n (%) 5 (2.2) 
  Past year illicit drug use, n (%) 11 (4.9) 
Pain measures  
  BPI severity score, mean ± SD [0-10] 5.4  ± 1.3 
  BPI interference score, mean ± SD [0-10] 5.5  ± 1.9 
  Abbreviated Roland-Morris score, mean ± SD [0-11] 8.3  ± 2.2 
Health related quality of life measures  
  VR12 physical score, mean ± SD [0-100] 27.1  ± 8.1 
  VR12 mental score, mean ± SD [0-100] 47.6  ± 12.1 
Mental health measures, n (%)  
   Positive depression screen (PHQ-9 score ≥10) 53 (22.1) 
   Positive anxiety screen (GAD-7 score ≥10) 22 (9.2) 
   Positive PTSD screen (PC-PTSD ≥3) 50 (20.8%) 
Arm preference, n (%)  
  Unsure/no preference 123 (51.3) 
  Prefers opioid arm 69 (28.8) 
  Prefers non-opioid arm 48 (20.0) 
Perceptions of treatment arms, mean ± SD   
  Opioid effectiveness [0-10] 7.8  ± 2.0 
  Opioid safety [0-10] 5.8  ± 2.6 
  Non-opioid effectiveness [0-10] 5.7  ± 2.7 
  Non-opioid safety [0-10] 6.6  ± 2.8 
Likely personal improvement, mean ± SD [0-10]  7.5  ± 1.9 
All values are self-reported. For continuous scale scores, the minimum to maximum score range is given 
in brackets, with the worst possible score bolded. 
*Participants with pain in both areas self-identified one location as primary. 
 
 
4. Discussion  
This trial is the first to evaluate long-term opioid therapy compared with long-term non-opioid 
medication therapy for chronic musculoskeletal pain. This study was designed as a pragmatic 
trial to overcome limitations common in prior opioid therapy trials. Key design features include 
comparing two clinically-relevant medication interventions that represent important competing 
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pain treatment approaches and incorporating flexibility into interventions to maximize relevance 
to clinical practice, benefits to participants, and, potentially, trial retention. The outcome 
assessment follow-up protocol was more structured (i.e., less pragmatic) in order to 
comprehensively assess multidimensional pain outcomes and conduct a detailed patient-reported 
and objective assessment of numerous potential opioid harms and adverse effects. 
 
Experts have previously suggested that recruiting for a long-term trial of opioid therapy would 
likely be difficult; we found this prediction to be true. To enroll 265 patients, we attempted to 
contact 5567 and conducted telephone eligibility screening interviews with 4491. Our 
recruitment strategy allowed us to screen thousands of potentially eligib le patients in a relatively 
efficient process. An additional advantage of this process is that we are able to describe 
characteristics of the population from which our study sample was drawn, thereby illuminating 
differences between the enrolled trial participants and non-enrolled patients.  
 
Our pragmatic eligibility criteria were intended to enroll a study sample with characteristics 
similar to those of the patient population receiving opioids in primary care practice. Prior 
randomized controlled trials of opioid analgesics have typically excluded patients with current 
mental health diagnoses or a history of substance use disorder. In contrast, patients with these 
conditions often receive opioids in practice. For example, an observational study of VA patients 
with chronic pain receiving opioids in 2009-2011 reported diagnoses of PTSD in 20.9%, 
depression in 32%, and non-opioid substance use disorder in 7.8%.16 Similarly, a study of VA 
patients who were new opioid recipients in 2011 reported diagnosed anxiety disorder in 9.4%, 
depressive disorder in 10.6%, and substance use disorder in 12.3%.63 High psychiatric 
comorbidity (e.g., depression in 8.5%, anxiety in 6.9%) among opioid recipients was also 
demonstrated in a national database of health insurance claims of more than 10 million patients 
receiving opioid prescriptions.64 Our rates of past-year PTSD (9.4%), anxiety disorder (17%), 
depression (28.3%), alcohol use disorder (7.9%) and drug use disorder (2.6%) diagnoses suggest 
that we were at least partially successful in recruiting patients similar to those receiving opioids 
in both VA and non-VA usual care.  
 
In planning this trial, we considered an alternative design that would have included intervention 
delivery by patients’ primary care clinicians. This approach would have been more pragmatic, 
but we decided against it for two main reasons. First, the alternative design would likely have 
necessitated clinician- level cluster randomization, which introduces additional risk of bias.65,66 
Second and most importantly, we were concerned about whether primary care clinicians would 
deliver the interventions with sufficient fidelity. Our decision was informed by a prior trial of 
two opioid prescribing strategies—stable dose versus liberal dose escalation—that used pain 
clinic providers to deliver the opioid prescribing interventions.12 In that study, the treatment 
groups separated in terms of opioid dosing over time (17 mg/day mean difference between 
groups), but both groups had small-to-moderate dose escalations during the trial and, arguably, 
neither group received a true “stable dose” or “liberal dose escalation” prescribing strategy. 
Ultimately, we used research personnel for intervention delivery to maximize the likelihood that 
participants would receive the intervention to which they were assigned.  
 
A major potential limitation of this study is that participants could not practicably be masked, 
due to the complexity and pragmatic nature of the medication interventions. Patient-reported 
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outcomes are thus subject to placebo and nocebo effects associated with expectations and 
perceptions. Pre-randomization arm preferences, treatment perceptions, and outcome 
expectations may provide potential insight into our eventual results. We find it interesting that 
participants had such high expectations of personal improvement at baseline. Less surprising to 
us, participants perceived opioids as having higher effectiveness for pain than non-opioid 
medications.  
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Figure 1: PRECIS-2 diagram* 
 
 
 
 
 
 
* The PRECIS-2 wheel is a visual representation of pragmatic design. Points near the rim of the 
circle represent more pragmatic design choices.   
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Figure 2: Screening and recruitment 
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